CRC Credit Research Compendium
Menu
日本語English

Issuer Credit Research

Great Eastern Life Issuer Flash: 1Q 2026 Results

Great Eastern Life Issuer Flash: 1Q 2026 Results

Report date: 2026-05-14 Event date: 2026-05-06 Event title: Q1 2026 Results

Flash Conclusion

For Great Eastern Life (GEL), the 1Q 2026 results released by Great Eastern Holdings Limited (GEH) on 2026-05-06 do not materially change the latest issuer_summary view that the issuer credit profile remains high quality and broadly stable, while investment markets, medical claims, regulatory capital, and capital-securities terms require continued monitoring. Insurance business profit and new business embedded value were strong, but the sharp decline in shareholders' fund profit and the OCI loss indicate that comprehensive income and reported capital remain sensitive to interest-rate, equity, and bond valuation movements.

The credit read-through is a combination of a mildly positive confirmation of insurance fundamentals and a mildly negative confirmation of market sensitivity. TWNS in 1Q-26 was S$401.9mn, up 16% year on year, while NBEV was S$195.4mn, up 31%. Profit from insurance business was also S$329.0mn, up 33%. By contrast, profit from shareholders' fund fell 82% year on year to S$17.3mn, and OCI was a loss of S$2.6mn. Because this analysis is based on GEH consolidated disclosure rather than GEL standalone 1Q financials, GEH consolidated profit, OCI, TWNS, and NBEV should not be treated as GEL standalone figures.

What Was Announced

On 2026-05-06, GEH announced its 1Q-26 financial results for the quarter ended 2026-03-31.

Key figures were as follows.

Metric 1Q-26 1Q-25 YoY
Total Weighted New Sales S$401.9mn S$345.1mn +16%
New Business Embedded Value S$195.4mn S$148.8mn +31%
Profit from Insurance Business S$329.0mn S$246.8mn +33%
Profit from Shareholders' Fund S$17.3mn S$98.7mn -82%
Group Profit Attributable to Shareholders S$346.3mn S$345.5mn broadly flat
Other Comprehensive Income -S$2.6mn S$73.9mn nm
Total Comprehensive Income S$343.7mn S$419.4mn -18%

The company explained that TWNS growth reflected continued momentum in Singapore, particularly productivity improvements in Agency and Banca. Malaysia was broadly flat amid weaker market sentiment. Profit from insurance business was supported by profit emergence from the in-force book and reserve releases reflecting positive experience variances, while profit from shareholders' fund declined mainly due to mark-to-market losses on equities and bonds. On regulatory capital, the disclosure was limited to a qualitative statement that the Capital Adequacy Ratios of the group insurance subsidiaries remained above their respective minimum regulatory requirements.

Credit Read-Through

First, the results reinforce the latest issuer_summary view on GEL's core insurance strength. GEL is the core Singapore life insurance subsidiary of the GEH group, and GEH's consolidated sales and insurance profit indicate that the insurance franchise, centred on Singapore, remains intact.

Second, the increase in insurance profit is positive, but the nature of the reserve releases should be read cautiously. The disclosure does not provide sufficient detail on which factors improved among medical claims, lapses, mortality and morbidity, expenses, and reinsurance. A single quarter is not enough to conclude that medical-claims risk has receded.

Third, market sensitivity remains a key constraint. Overall net profit was broadly flat, but this reflected stronger insurance business profit absorbing weakness in the investment account. As a life insurer with large bond, equity, and fund investments, GEL remains exposed to the impact of higher interest rates, weaker equities, wider credit spreads, and bond valuation losses on earnings, OCI, TCI, and reported comprehensive capital.

Fourth, the regulatory-capital comment is reassuring, but the assessment is limited because numerical ratios were not disclosed. GEL standalone CAR/RBC, capital headroom by major GEH subsidiary, regulatory-capital recognition of AT1/Tier 2, and capital sensitivity under interest-rate and market stress remain unconfirmed.

The view on parent and group support is also unchanged. The relationship with OCBC supports the credit profile, but does not constitute an explicit guarantee of GEL securities. After the 1Q-26 results, the view on GEL's issuer credit profile remains "high quality and stable." The unchanged constraints are the analytical limitation from reliance on GEH consolidated data, the absence of GEL standalone capital data, the need to monitor medical claims and investment markets, and the fact that AT1/Tier 2 instruments cannot be equated with senior issuer credit risk.

What To Watch Next

The first item to monitor is whether the 1Q growth in NBEV and improvement in insurance business profit are sustained through 1H 2026 or the full year. Key points are Agency and Banca productivity in Singapore, weak demand in Malaysia, and the product mix behind NBEV growth.

Second is the composition of insurance business profit. The drivers of reserve releases, medical claims, loss component, reinsurance, lapse rates, expense assumptions, and changes in CSM can be assessed only to a limited extent from the current disclosure. The medical-claims risk identified as a key monitoring point in the latest summary is not resolved by this 1Q result alone.

Third, investment markets, OCI, TCI, and reported capital should be tracked. The deterioration in shareholders' fund profit and OCI showed sensitivity to bond and equity valuations. If interest rates continue to rise or credit spreads continue to widen, the focus will be on accounting valuation losses and the impact on CE and regulatory capital.

Fourth is GEL standalone public financials and regulatory capital. Confirmation of GEL standalone total assets, insurance contract liabilities, shareholders' equity, dividends, and regulatory capital ratios would improve the precision of the assessment from a GEH consolidated view to a GEL issuer-level view.

Fifth are the specific terms of the AT1/Tier 2 instruments. The 1Q result itself does not indicate concerns over distribution suspension or redemption, but the assessment of capital securities requires confirmation of distribution cancellation, non-cumulative features, MAS approval, first call, regulatory event, tax event, loss absorption, and liquidation ranking.

Sources

Unverified / Pending